FEMY

Femasys Inc

2.00

Oct 09 • 3:59 PM ET -0.05 (-2.20%)

1.95

Aftermarket • 7:30 PM ET -0.05 (-2.50%)

Healthcare Medical Instruments & Supplies USA Nano NASD

Peers: HBIO MLSS NEPH EMBC KRMD OSUR PDEX SMTI STXS UTMD

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	16.75M
Enterprise Value	20.10M
Income	-12.29M
Sales	2.30M
Book/sh	1.33
Cash/sh	0.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	Jun 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	7.28
P/B	1.50
P/C	11.63
P/FCF	-
EV/EBITDA	-
EV/Sales	8.74
Quick Ratio	0.55
Current Ratio	2.14
Debt/Eq	1.19
LT Debt/Eq	1.07
Option/Short	No / Yes

EPS (ttm)	-4.62
EPS next Y	-1.75
EPS next Q	-0.47
EPS this Y	75.78%
EPS next Y	23.13%
EPS next 5Y	49.37%
EPS past 3/5Y	21.27% 4.34%
Sales past 3/5Y	23.88% 17.18%
EPS Y/Y TTM	73.27%
Sales Y/Y TTM	21.86%
EPS Q/Q	58.08%
Sales Q/Q	-18.92%
Earnings	Aug 14 AMC
EPS/Sales Surpr.	-1.53% -54.59%

Insider Own	3.43%
Insider Trans	17.06%
Inst Own	46.80%
Inst Trans	32.55%
ROA	-94.25%
ROE	-443.65%
ROIC	-147.17%
Gross Margin	25.45%
Oper. Margin	-763.90%
Profit Margin	-534.27%
SMA20	-13.82%
SMA50	-23.03%
SMA200	-71.28%
Trades

Shs Outstand	8.38M
Shs Float	8.09M
Short Float	7.14%
Short Ratio	0.81
Short Interest	0.58M
52W High	22.20 -90.99%
52W Low	1.94 3.09%
Volatility	7.87% 7.55%
ATR (14)	0.21
RSI (14)	33.08
Beta	-2.20
Rel Volume	0.18
Avg Volume	711.43K
Volume	128,500

Perf Week	-2.44%
Perf Month	-27.01%
Perf Quarter	-42.36%
Perf Half Y	-74.81%
Perf YTD	-82.64%
Perf Year	-84.59%
Perf 3Y	-94.19%
Perf 5Y	-98.59%
Perf 10Y	-
Recom	1.00
Target Price	14.33
Prev Close	2.05
Price	2.00
Change %	-2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-25	Initiated	Laidlaw	Buy	$6.50

Oct-08-26 10:38AM	Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands (InvestorsHub)
09:00AM	Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo (GlobeNewswire)
Sep-15-26 09:00AM	Femasys Advances OB/GYN Expansion with Adoption of FemaSeed Fertility Portfolio by Minnesota Women's Care (GlobeNewswire)
Sep-09-26 09:00AM	Femasys Partners with CapexMD to Expand Patient Access to FemaSeed Fertility Portfolio (GlobeNewswire) +5.60%
Aug-26-26 09:00AM	Femasys Partners with UNC Health to Introduce Its FemaSeed Fertility Portfolio Across Statewide OB/GYN Care Locations (GlobeNewswire)
12:01PM	Loading…
Aug-19-26 12:01PM	FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology Retail Sees 500% Upside Potential (Stocktwits) +23.18%
10:37AM	Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc (InvestorsHub)
09:00AM	Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc (GlobeNewswire)
Aug-14-26 04:05PM	Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire) -5.68%
Aug-12-26 09:00AM	Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents (GlobeNewswire)
Aug-07-26 09:25AM	Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million (GlobeNewswire) -9.83%
Jun-24-26 09:00AM	Femasys Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -8.48%
May-13-26 09:00AM	Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG Catheter (GlobeNewswire)
May-08-26 04:05PM	Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update (GlobeNewswire) -5.98%
May-05-26 09:00AM	Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed Complete (GlobeNewswire) +7.42%
09:00AM	Loading…
Apr-22-26 09:00AM	Femasys Launches FemaSeed Complete for OB/GYNs at ACOG 2026 (GlobeNewswire)
Apr-16-26 09:00AM	Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio (GlobeNewswire)
Apr-01-26 09:00AM	Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth (GlobeNewswire)
Mar-31-26 04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update (GlobeNewswire) +11.76%
Mar-18-26 09:00AM	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors (GlobeNewswire)
Mar-10-26 09:00AM	Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment (GlobeNewswire)
Feb-27-26 05:26PM	Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Feb-26-26 09:00AM	Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access (GlobeNewswire)
Feb-23-26 09:00AM	Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination (GlobeNewswire)
Feb-03-26 09:15AM	Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products (GlobeNewswire)
Jan-14-26 09:00AM	Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +17.81%
Jan-13-26 09:00AM	Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed in Community-Based Care (GlobeNewswire)
Dec-18-25 09:15AM	Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device (GlobeNewswire)
Nov-25-25 09:15AM	PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment (Business Wire) +7.78%
Nov-14-25 04:01PM	Femasys Announces Third Quarter Financial Results for 2025 (GlobeNewswire) +8.58% -11.28%
09:00AM	Loading…
Nov-10-25 09:00AM	Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe (GlobeNewswire)
Nov-03-25 08:30AM	Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million (GlobeNewswire)
Oct-22-25 09:00AM	Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc Permanent Birth Control in Europe (GlobeNewswire) -9.57%
Oct-16-25 09:00AM	Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo (GlobeNewswire) +35.38%
Sep-25-25 09:00AM	Femasys Accelerates European Growth for FemBloc with Kebomed Partnership (GlobeNewswire)
Sep-23-25 09:20AM	Femasys partners with Medical Electronic Systems for FemSperm kit (TipRanks)
Sep-22-25 09:00AM	Femasys Partners with Medical Electronic Systems to Launch FemSperm Analysis Kit for use with FemaSeed (GlobeNewswire)
Sep-11-25 09:00AM	Femasys Expands FemSperm Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed (GlobeNewswire)
Sep-08-25 09:00AM	Femasys Secures Regulatory Approval for FemBloc Permanent Birth Control in New Zealand (GlobeNewswire)
Sep-02-25 09:00AM	Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios (GlobeNewswire) +12.62%
Aug-27-25 12:02PM	Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale (Insider Monkey)
Aug-25-25 11:44PM	Femasys Announces Pricing of $8.0 Million Underwritten Public Offering (GlobeNewswire) -9.79% -27.00%
Aug-21-25 09:00AM	Femasys Announces FemSperm Kit to Activate Gynecologists and Advance FemaSeed Fertility Platform (GlobeNewswire) -8.66%
Aug-20-25 09:00AM	Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control (GlobeNewswire) -7.38%
Aug-08-25 05:15PM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -13.16%
04:05PM	Femasys Announces Second Quarter Financial Results for 2025 (GlobeNewswire)
Aug-07-25 09:25AM	Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.33%
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion (GlobeNewswire)
Jul-01-25 09:00AM	Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed for First-Line Infertility Treatment and FemVue Diagnostic (GlobeNewswire)
Jun-25-25 09:00AM	Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control (GlobeNewswire) +10.71%
Jun-17-25 09:00AM	Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth (GlobeNewswire)
Jun-11-25 09:00AM	Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations (GlobeNewswire) +6.25%
May-30-25 08:00AM	Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million (GlobeNewswire) -13.73%
May-29-25 04:23PM	Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.83%
05:01PM	Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update (GlobeNewswire)
May-06-25 09:05AM	Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates (Zacks)
Mar-27-25 10:10AM	Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -12.17%
09:00AM	Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update (GlobeNewswire)
Mar-20-25 11:06AM	Femasys price target raised to $15 from $12 at H.C. Wainwright (TipRanks)
Mar-19-25 09:20AM	Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
09:00AM	Femasys Secures Distribution Partnerships for Commercialization of FemBloc in Spain (GlobeNewswire)
Mar-13-25 08:30AM	Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach (GlobeNewswire)
Feb-25-25 09:20AM	Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials (GlobeNewswire)
Feb-11-25 09:00AM	Femasys Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire) +7.76%
Feb-05-25 07:28AM	Femasys gains approvals for infertility and diagnostic products in Israel (Medical Device Network) +6.19%
Feb-04-25 09:00AM	Femasys Announces Israeli Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire)
Jan-30-25 08:30AM	Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control (GlobeNewswire)
Jan-16-25 08:30AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment (GlobeNewswire)
Dec-03-24 09:00AM	Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed (GlobeNewswire)
Nov-26-24 08:30AM	Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment (GlobeNewswire)
Nov-12-24 09:45AM	Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -11.59%
08:30AM	Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update (GlobeNewswire)
Nov-07-24 08:30AM	Femasys to Exhibit at the Annual AAGL 2024 Global Conference (GlobeNewswire)
Nov-01-24 08:30AM	Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control (GlobeNewswire) -5.26%
Oct-30-24 09:00AM	Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed (GlobeNewswire)
Oct-10-24 08:30AM	Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program (GlobeNewswire)
Oct-08-24 08:30AM	Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed Infertility Treatments (GlobeNewswire)
Sep-18-24 08:30AM	Femasys Announces Infertility Clinic Customers from Coast to Coast (GlobeNewswire)
Sep-11-24 08:30AM	Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market (GlobeNewswire) +7.48%
Sep-09-24 11:53AM	FDA clears FemChec for fallopian tube occlusion testing (Medical Device Network)
08:30AM	Femasys Inc. Receives U.S. FDA Clearance to Market FemChec , an Innovative Diagnostic Solution for Fallopian Tube Check (GlobeNewswire)
Sep-05-24 08:30AM	Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting (GlobeNewswire)
Sep-03-24 08:30AM	Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.84%
Aug-30-24 06:32AM	Femasys secures CE mark certification for FemVue MINI solution (Medical Device Network)
Aug-29-24 08:30AM	Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution (GlobeNewswire) +10.48%
Aug-27-24 08:30AM	Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters (GlobeNewswire)
Aug-08-24 09:45AM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -18.09%
08:30AM	Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:30AM	Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam (GlobeNewswire) +10.58%
Jun-21-24 04:32AM	Femasys gains CE Mark approval for womens health products (Medical Device Network) -9.45%
Jun-20-24 08:30AM	Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe (GlobeNewswire) +32.98%
May-17-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative (GlobeNewswire)
May-16-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council (GlobeNewswire)
May-09-24 01:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.63%
09:40AM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

FounderMs. Kathy Lee-Sepsick M.B.A.

Chief Financial OfficerMr. Dov Elefant

Chief Operating OfficerMr. John Canning

Chief Technology OfficerMr. Jeremy Alexander Sipos M.S.

Chief Medical OfficerDr. James H. Liu M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mifek Jeffrey Gerald	Chief Clinical-Medical Affairs	Aug 07 '26	Buy	3.20	3,125	10,000	3,125	Aug 11 08:54 PM
Sipos Jeremy Alexander	Chief Technology Officer	Aug 07 '26	Buy	3.20	3,125	10,000	3,125	Aug 11 08:44 PM
Canning John Charles	Chief Operating Officer	Aug 07 '26	Buy	3.20	4,375	14,000	4,375	Aug 11 08:40 PM
Elefant Dov	Chief Financial Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625	Aug 11 08:37 PM
Lee-Sepsick Kathy	Chief Executive Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625	Aug 11 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FEMY

Femasys Inc

Upgrade your Finviz experience